Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age

Introduction: The human papillomavirus (HPV) vaccine has been reported to lead to clinical clearance of lesions when used as an off-label treatment for recalcitrant extragenital warts. The aim of the study is to evaluate the therapeutic and adverse effects of HPV vaccine as an adjunctive therapy for treatment-resistant acral warts. Methods: Patients with persistent warts despite first and second line therapies, and subsequently receiving the quadrivalent HPV vaccine between July 2013 and June 2016 as an adjunctive treatment for recalcitrant warts at the National Skin Centre, were included. Results: Twenty-six patients with a median age of 34 years (range 8 to 77 years) were treated with the HPV vaccine. Nineteen (73.1%) patients completed 3 doses of the vaccine, of whom 5 (26%) achieved complete clearance, 8 (42%) had partial clearance and 6 (32%) did not respond to the vaccine. Among the 4 patients who received 2 doses of the vaccine, 3 (75%) had complete clearance whereas 1 (25%) had partial improvement of their warts. None of the patients reported adverse reactions. Conclusion: Our study suggests a potential adjunctive role of the HPV vaccine in the treatment of acral warts recalcitrant to conventional therapy. Keywords: Acral warts, HPV vaccine, quadrivalent vaccine, recalcitrant warts

Download Full-text

Vaccine Hesitancy and Differential Susceptibility to Media Coverage: A Critical Documentary Led to Substantial Reductions in Human Papillomavirus Vaccine Uptake in Denmark

Medical Decision Making ◽

10.1177/0272989x211003589 ◽

2021 ◽

pp. 0272989X2110035

Author(s):

Maria Knoth Humlum ◽

Niels Skipper ◽

Peter Rønø Thingholm

Keyword(s):

Human Papillomavirus ◽

Hpv Vaccine ◽

Media Coverage ◽

Differential Susceptibility ◽

Vaccine Uptake ◽

Vaccine Hesitancy ◽

Human Papillomavirus Vaccine ◽

Policy Makers ◽

Quasi Experimental ◽

Papillomavirus Vaccine

Objectives To investigate whether negative media coverage of the human papillomavirus (HPV) vaccine led to a decrease in the uptake of the first dose of the HPV vaccine (HPV1) in Denmark and, importantly, whether some groups of individuals were more susceptible to negative media coverage. Methods We measured HPV vaccine uptake of 12-year-old girls born in 2001 to 2004 using Danish administrative data. A quasi-experimental design was employed to assess whether a documentary that was critical of the HPV vaccine and aired in March 2015 affected HPV uptake. Results The documentary led to a quick and substantial decrease in the monthly propensity to vaccinate, which dropped 3 percentage points—or about 50%—in response to the documentary. Responses differed substantially across subgroups, and girls from families with high socioeconomic status (SES) were more susceptible to the negative media coverage. Conclusions Susceptibility to negative media coverage varied substantially across subgroups, highlighting the need for policy makers to appropriately target and differentiate initiatives to improve vaccine compliance rates.

Download Full-text

A Case of Myopericarditis and the HPV vaccine

Medical Research Archives ◽

10.18103/mra.v9i12.2649 ◽

2021 ◽

Vol 9 (12) ◽

Author(s):

Angela Pegram ◽

Tara Bush

Keyword(s):

Human Papillomavirus ◽

Social History ◽

Hpv Vaccine ◽

Package Insert ◽

Human Papillomavirus Vaccine ◽

T Wave ◽

Dose Number ◽

Males And Females ◽

Artery Disease ◽

Papillomavirus Vaccine

Introduction: Human Papillomavirus (HPV) is the underlying etiology of numerous cancers and genital warts in both males and females. Vaccines were developed against HPV to prevent transmission and arrest development of cancers caused by the virus. Gardasil 9â is the newest vaccine, covering 9 serotypes of HPV and is recommended by the CDC for both males and females over 9 years of age in a series of vaccinations. Myopericarditis (including myocarditis and pericarditis) is not reported as an adverse reaction in the Gardasil 9â package insert. Case Report A healthy 18-year-old male with no significant past medical or social history received dose number 3 of HPV vaccine at his physician’s office. Within 24 hours, he developed chills and a fever (normal HPV reactions) and then recovered without sequelae within 48 hours. Three days later, he developed crushing chest pain, with arm tingling and jaw pain. He was triaged directly to the emergency room where he had troponins of greater than 11000 and T wave inversions on his EKG. Other diagnostic tests and labs showed normal heart anatomy and no early coronary artery disease. He was diagnosed with myopericarditis by cardiology. He was treated and recovered fully within 3 months. Discussion Using the WHO tool for adverse vaccine reactions, this case has a consistent causal relationship with vaccination. This is the eleventh case of myopericarditis reported to the Vaccine Adverse Effects Reporting system for the HPV vaccine. Conclusion Although rare, myopericarditis should be considered as a possible adverse effect from the human papillomavirus vaccine.

Download Full-text

962. Trends in Cervical Pre-cancers by Race and Ethnicity During the Human Papillomavirus Vaccine Era, HPV Vaccine Impact Monitoring Project (HPV-IMPACT), United States, 2008–2016

Open Forum Infectious Diseases ◽

10.1093/ofid/ofz359.064 ◽

2019 ◽

Vol 6 (Supplement_2) ◽

pp. S29-S29

Author(s):

Julia Gargano ◽

Rayleen Lewis ◽

Hillary Hunt ◽

Nancy McClung ◽

Nancy M Bennett ◽

...

Keyword(s):

United States ◽

Human Papillomavirus ◽

Hpv Vaccine ◽

The United States ◽

Adenocarcinoma In Situ ◽

Human Papillomavirus Vaccine ◽

Impact Monitoring ◽

Vaccine Impact ◽

Race Ethnicity ◽

Papillomavirus Vaccine

Abstract Background Since human papillomavirus (HPV) vaccine introduction in the United States in 2006, cervical pre-cancer incidence has declined in young women, but pre-cancer trends have not been reported by race/ethnicity. We evaluated trends in cervical pre-cancers from 2008 to 2016 in non-Hispanic (NH) white, NH black, NH Asian, and Hispanic women identified through active population-based surveillance in the 5-site Human Papillomavirus Vaccine Impact Monitoring Project (HPV-IMPACT). Methods We analyzed data on cervical intraepithelial neoplasia (CIN) grades 2–3 and adenocarcinoma in situ (CIN2+) cases aged 20–39 years. Annual CIN2+ rates per 100,000 women were calculated stratified by race/ethnicity in 5-year age groups, using multiple imputation to account for 10% missing race/ethnicity data. Rates were also calculated using estimated numbers screened for cervical cancer to control for known declines in screening. Trends, evaluated using JoinPoint software, are presented as average annual percentage changes (AAPC) with 95% confidence intervals (CI). Results A total of 18,222 CIN2+ cases (62% NH white, 16% NH black, 16% Hispanic, 6% Asian) were reported from 2008 to 2016. CIN2+ rates among 20–24 year-olds declined significantly in all groups: NH white, AAPC: −14.2 (95% CI: −16.3, −12.1); NH black, AAPC: −15.5 (−19.5, −11.4); Asian, AAPC: −14.8 (−20.5, −8.8); Hispanic, AAPC: −14.3 (−17.9, −10.5). In 25–29 year olds, a significant decline was observed for NH whites only (AAPC: −2.4, [−4.0, −0.8]). No declines were seen in 30–34 or 35–39 year olds. Among screened 20–24 year-olds, significant but smaller declines were observed (AAPC: −9.8 to −8.4); no declines were observed in screened 25–29 year olds or older groups. Conclusion In this evaluation of CIN2+ trends by race/ethnicity during the HPV vaccine era, the significant declines in 20–24 year olds across all groups, including among screened women, is consistent with equitable vaccine impact on CIN2+. Disclosures All Authors: No reported Disclosures.

Download Full-text

Bioethics Human Papillomavirus and HPV Vaccine

Journal of Regenerative Biology and Medicine ◽

10.37191/mapsci-2582-385x-1(1)-002 ◽

2019 ◽

Author(s):

Christine Shanahan Davies

Keyword(s):

Human Papillomavirus ◽

Hpv Vaccine ◽

Ethical Issues ◽

Social Issues ◽

Scientific Evidence ◽

Ethical Question ◽

Clinical Aspects ◽

Human Papillomavirus Vaccine ◽

Family Nurse Practitioner ◽

Papillomavirus Vaccine

This paper will discuss what the Human Papillomavirus (HPV) is. Ethical questions posed are “Should the HPV (Human Papillomavirus) vaccine be required? If yes at what age and should it be required for both boys and girls? During the paper another ethical question that will be discussed is, “On what basis should parents be permitted to refuse and be exempt from the mandate”? An analysis of the Human papillomavirus will explain what is HPV, how it is passed between people, any symptoms that could occur, and information about treatment, vaccines, and prevention. The role and responsibilities of the Family Nurse Practitioner, clinical aspects, scientific evidence, conflicts, social issues, contextual facts and stakeholders will all be discussed. In addition bioethical principles autonomy, informed consent, beneficence, non-malfeasance, and justice will be discussed that are relevant and applicable to the ethical issues associated with the Human papillomavirus and HPV vaccine.

Download Full-text

Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance

Sexual Health ◽

10.1071/sh09153 ◽

2010 ◽

Vol 7 (3) ◽

pp. 320 ◽

Cited By ~ 16

Author(s):

Michael S. Gold ◽

Jim Buttery ◽

Peter McIntyre

Keyword(s):

Human Papillomavirus ◽

Hpv Vaccine ◽

Case Series ◽

Vaccine Safety ◽

Age Group ◽

Human Papillomavirus Vaccine ◽

Federally Funded ◽

Conversion Disorders ◽

Passive Surveillance System ◽

Papillomavirus Vaccine

Australia was one of the first countries to licence a quadrivalent human papillomavirus (HPV) vaccine, rapidly followed by a federally funded program of universal vaccination of a broad age group of females through schools (12 to 18 years) and primary care (19 to 26 years). As of August 2009, more than 5.8 million doses of Gardasil® (quadrivalent; Merck, New Jersey, USA) have been distributed in Australia and a total of 1394 suspected adverse events following immunisation (AEFI) have been reported to the passive surveillance system. Most reports are of common and expected reactions. Case series of more uncommon and serious AEFI, both known to be potentially vaccine related (anaphylaxis, conversion disorders and lipoatrophy) and otherwise (multiple sclerosis and pancreatitis) have been published.

Download Full-text

Attitudes about human papillomavirus vaccine in young women

International Journal of STD & AIDS ◽

10.1258/095646203321605486 ◽

2003 ◽

Vol 14 (5) ◽

pp. 300-306 ◽

Cited By ~ 180

Author(s):

Jessica A Kahn ◽

Susan L Rosenthal ◽

Tara Hamann ◽

David I Bernstein

Keyword(s):

Human Papillomavirus ◽

Young Women ◽

Hpv Vaccine ◽

Hpv Vaccination ◽

Human Papillomavirus Vaccine ◽

Chi Square ◽

Positive Attitudes ◽

Number Of Sexual Partners ◽

Papillomavirus Vaccine ◽

To Receive

Human papillomavirus (HPV) vaccines are under investigation, but little is known about attitudes regarding vaccination. The aims of this study were to identify attitudes about and intention to receive an HPV vaccine in young women using a theory-based model. Young women ( n=52, mean age 25 years, range 18-30 years, 35% Black/Non-Hispanic) completed a survey assessing knowledge, attitudes about HPV vaccination, and risk behaviours. Associations between attitudes and intention to receive the vaccine were assessed using Mann-Whitney U or chi-square tests. Subjects reported positive attitudes about receiving an HPV vaccine and high intention to receive the vaccine both for themselves and their daughters. Variables associated significantly with intention included knowledge ( P=0.004), personal beliefs about vaccination ( P=0.004), belief that others would approve of vaccination ( P=0.005), and higher number of sexual partners ( P=0.028). Information on attitudes about HPV vaccination and predictors of intention to receive a vaccine may guide immunization initiatives for young adults.

Download Full-text

Tracking the Human Papillomavirus Vaccine Risk Misinformation: An Explorative Study to Examine How the Misinformation Has Spread in User-Generated Content

Proceedings of the International Symposium on Human Factors and Ergonomics in Health Care ◽

10.1177/2327857920091069 ◽

2020 ◽

Vol 9 (1) ◽

pp. 312-316

Author(s):

Jessie Chin ◽

Chieh-Li Chin ◽

Sakshi Panday ◽

Anoosheh Ghazanfari ◽

Ganesh Jagadeesan ◽

...

Keyword(s):

Human Papillomavirus ◽

Language Processing ◽

Hpv Vaccine ◽

Human Papillomavirus Vaccine ◽

Hpv Vaccines ◽

Network Analyses ◽

Explorative Study ◽

Related Information ◽

Vaccine Information ◽

Papillomavirus Vaccine

The goal of the study is to identify and track the dissemination patterns of true and false information about Human Papillomavirus (HPV) vaccines on twitter from 2013 to 2017. We applied a patient-driven HPV-vaccine risk lexicon combining with natural language processing (NLP) models and network analyses to explore the spread of verified true and false HPV-vaccine information. The explorative analyses showed different dissemination patterns of the most popular verified true and false messages about HPV vaccines, which false messages went viral than the true messages. Implications on detecting false HPV-vaccine related information were also discussed.

Download Full-text

Human Papillomavirus Vaccine Effectiveness Against HPV Infection: Evaluation of One, Two, and Three Doses

The Journal of Infectious Diseases ◽

10.1093/infdis/jiz555 ◽

2019 ◽

Vol 221 (6) ◽

pp. 910-918 ◽

Cited By ~ 4

Author(s):

Lauri E Markowitz ◽

Allison L Naleway ◽

Nicola P Klein ◽

Rayleen M Lewis ◽

Brad Crane ◽

...

Keyword(s):

Human Papillomavirus ◽

Hpv Vaccine ◽

Hpv Infection ◽

Vaccine Effectiveness ◽

Human Papillomavirus Vaccine ◽

Specimen Collection ◽

National Programs ◽

Collection Date ◽

Papillomavirus Vaccine ◽

Prevalence Ratios

Abstract Background Highly effective human papillomavirus (HPV) vaccines are used in many national programs in 3- or 2-dose schedules. We examined HPV vaccine effectiveness against HPV prevalence by number of doses. Methods We collected residual liquid-based cytology samples from US women aged 20–29 years who were screened for cervical cancer. Women continuously enrolled from 2006 through the specimen collection date were analyzed. Specimens were tested using the Linear Array assay. We analyzed prevalence of quadrivalent HPV vaccine (4vHPV) types (HPV 6,11,16,18) and other HPV-type categories and determined prevalence ratios (PRs) and 95% confidence intervals (CIs) for 1, 2, and 3 compared with no vaccine doses. Results Among 4269 women, 1052 (24.6%) were unvaccinated, 2610 (61.1%) received 3 doses, 304 (7.1%) received 2 doses, and 303 (7.1%) received 1 dose. The 4vHPV-type prevalence was 7.4% among unvaccinated women compared with 1.7%, 1.0%, and 1.0% among 1-, 2-, and 3-dose recipients. Among women vaccinated at ≤18 years, adjusted PRs for 1, 2, and 3 doses were 0.06 (95% CI, 0.01–0.42), 0.05 (95% CI, 0.01–0.39), and 0.06 (95% CI, 0.04–0.12). Conclusions Among women who received their first dose at age ≤18, estimated HPV vaccine effectiveness was high regardless of number of doses.

Download Full-text

Human papillomavirus vaccine timing associated with eventual human papillomavirus diagnosis in women

International Journal of STD & AIDS ◽

10.1177/0956462420937168 ◽

2020 ◽

Vol 31 (10) ◽

pp. 976-981

Author(s):

Robert J Zeglin ◽

Juliet L Fetteroll

Keyword(s):

Human Papillomavirus ◽

Hpv Vaccine ◽

Sexual Debut ◽

Secondary Data ◽

Hpv Infection ◽

Nutrition Examination Survey ◽

Human Papillomavirus Vaccine ◽

Vaccination Rates ◽

Health And Nutrition ◽

Papillomavirus Vaccine

Nearly all cases of cervical cancer are attributable to human papillomavirus (HPV), making it a significant women’s health issue. Though there have been advances in the prevention of HPV via vaccination, significant barriers continue to suppress vaccination rates for girls. Delaying vaccination until after sexual debut increases a woman’s chance of HPV infection, but there has been no quantification of this risk in the literature. The present study sought to address this gap via secondary data analysis with 173 female participants from the 2015–2016 National Health and Nutrition Examination Survey dataset. Results indicate that women in the sample who received the HPV vaccine after their sexual debut were 2.63 times more likely than women who receive the vaccine before their sexual debut to report an HPV diagnosis. These results have clear public and sexual health implications.

Download Full-text